Phase II Neoadjuvant Pyrotinib Combined With Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial

Breast Cancer Clinical Trial

Official title:

Phase II Neoadjuvant Pyrotinib Combined With Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05165225
• Other study ID #: PILHLE-001
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: July 13, 2021
• Est. completion date: March 31, 2028

Study information

• Verified date: November 2023
• Source: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-arm, prospective, non-randomized, single-center, open label clinical study for evaluating the efficacy and safety of neoadjuvant pyrotinib combined with epirubicin and cyclophosphamide followed by docetaxel in HR positive and HER2-low-expressing early or locally advanced breast cancer.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 48
• Est. completion date: March 31, 2028
• Est. primary completion date: September 30, 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Written informed consent for all study according to local regulatory requirements prior to beginning specific protocol procedures

2. Female patients, age = 18 years

3. Histologically confirmed unilateral primary carcinoma of the breast, except for occult breast cancer, inflammatory breast cancer without assessable focus or eczema like breast cancer

4. HER2-low-positive (defined here as HER2 IHC 2+ and FISH-) and HR positive(defined here as ER and/or PR >1% stained cells)

5. Tumour greater than 2 cm diameter or histologically (core- or fine-needle biopsy) involved lymph nodes

6. According to RECIST version 1.1, there is at least one evaluable target lesion

7. Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-1

8. Required laboratory values including following parameters: WBC count:=3.0 x 10^9/L ; ANC: = 1.5 x 10^9/L; Platelet count: = 100 x 10^9/L; Hemoglobin: = 9.0 g/dL; Total bilirubin: = 1.5 x upper limit of normal (ULN); ALT and AST: = 2.5 x ULN; alkaline phosphatase = 2.5 × ULN; Serum creatinine: = 1.5 × ULN; Left ventricular ejection fraction (LVEF) = 55%

9. For female patients without menopause or surgical sterilization: consent to contraception both during the trial and within 6 months after the last administration of the test drug

Exclusion Criteria:

1. Metastatic disease (Stage IV) or bilateral breast cancer

2. Known history of hypersensitivity to pyrotinib or any of it components

3. According to the judgment of the researcher, other anti-tumor treatments (except for ovarian function inhibitors) are required during neoadjuvant therapy

4. Patients with severe heart disease or discomfort who are expected to be unable to tolerate chemotherapy, including but not limited to these: 1). Fatal arrhythmia or higher grade atrioventricular block (second degree type 2 atrioventricular block or third degree atrioventricular block) 2). Unstable angina pectoris 3). Heart valve disease with clinical significance 4). ECG showed transmural myocardial infarction pain 5). Poor control of hypertension

5. Patients underwent major breast cancer-free surgery within 4 weeks or have not fully recovered

6. Serious or uncontrolled infections that may affect study treatment or evaluation of study results, including but not limited to active hepatitis virus infection, human immunodeficiency virus (HIV) antibody positive, lung infection, etc

7. History of other malignant tumors in the past 5 years (excluding cured carcinoma in situ of cervix or skin basal cell carcinoma)

8. Those with basic gastrointestinal diseases (especially long-term history of diarrhea or/and constipation);Inability to swallow?intestinal obstruction or other factors will affect drug administration and absorption

9. The investigator believes that the patient has any other conditions that are not suitable for participation in the study

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms
• Hormone Receptor-positive Breast Cancer
• Neoadjuvant Therapy

Intervention

Drug:
• Pyrotinib + epirubicin and cyclophosphamide followed by docetaxel treatment
Drug: Pyrotinib pyrotinib 320mg orally daily Drug: Epirubicin epirubicin 90mg/m^2 d1 iv Q3W for 4 cycles Drug: Cyclophosphamide cyclophosphamide 600mg/m^2 d1 iv Q3W for 4 cycles Drug: Docetaxel docetaxel 100mg/m^2 d1 iv Q3W for 4 cycles

Locations

Country	Name	City	State
China	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Guangzhou	Guangdong

Sponsors (2)

Lead Sponsor	Collaborator
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Jiangsu HengRui Medicine Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Residual cancer burden 0/1 (RCB-0/1) rate	The percentage of patients with RCB-0/1 after neoadjuvant therapy	within 6 weeks after surgery
Secondary	Pathological complete response (pCR) rate	The percentage of patients with pCR (ypT0/is, ypN0) after neoadjuvant therapy	within 6 weeks after surgery
Secondary	Objective response rate (ORR)	The percentage of subjects with CR or PR as the best response during the period from the beginning of the treatment to the progression of the disease or the completion of preoperative neoadjuvant therapy ?(CR+PR)/Analysis of the total number of people?	within 6 weeks after surgery
Secondary	Breast conservation rate.	The breast conservation rate after treatment.	within 6 weeks after surgery
Secondary	Disease-free Survival (DFS)	The DFS is defined as the time from registration until any relapse, secondary malignancy, or death from any cause	5 years
Secondary	Overall Survival (OS).	The OS is defined as the time from registration to death, irrespective of cause.	5 years
Secondary	Biomarkers	Biomarkers: e.g. Tils	5 years
Secondary	Incidence of grade 3-5 diarrhea.	Diarrhea were graded according to the National Cancer Institute's Common Toxicity Criteria for Adverse Events (CTCAE) version 5.0.	before surgery